Dezocine as preemptive analgesia alleviates ultrapulse CO 2 fractional laser treatment induced pain in patients with acne scars
Journal of Cosmetic Dermatology · 2024
DOI: 10.1111/jocd.16410 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2024. Verfasst von Qian Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Acne Vulgaris, Lasers, Gas, Cicatrix, Tetrahydronaphthalenes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Ultrapluse CO 2 fractional laser technology has emerged as an effective treatment for scar management. However, one drawback of this modality is the pain caused during the procedure. This study aims to explore the efficacy and safety of dezocine (DZC) as preemptive analgesia for reduction of pain induced by ultrapulse CO 2 fractional laser treatment for acne scars.
Methods
The study cohort included 78 outpatients with acne scars between February and April 2023. Patients were randomly assigned into three groups with intravenous injection (iv) of DZC prior to laser treatment: (1) control, iv of saline; (2) DZC group 1 (DZC_1), iv of DZC at 0.15 mg/kg; and (3) DZC_2, iv of DZC at 0.20 mg/kg. After 30 min, one session of ultrapulse CO 2 fractional laser treatment on acne scars was performed. Hemodynamics, visual analogue scale (VAS), and anxiety visual analog test (AVAT) were monitored prior to, during, and after the procedure.
Results
Operative success rates for patients in the control, DZC_1, and DZC_2 groups were 34.6%, 84.6%, and 100%, respectively. DZC administered with either dosage significantly reduced the VAS and AVAT scores of patients in treatment groups as compared with the subjects in the control group during the course of ultrapulse CO 2 fractional laser treatment. Patients in DZC_1 and DZC_2 groups did not show any significant difference in hemodynamic parameters, VAS, and AVAT scores. Temporary adverse effects such as nausea and dizziness were observed in some subjects after treatment; the symptoms were quickly dissolved after a rest in supine position.
Conclusions
DZC as preemptive analgesia could effectively reduce pain and anxiety induced by ultrapulse CO 2 fractional laser treatment in patients. This study provided an option of preemptive anesthesia to minimize the pain and discomforts associated with laser treatments in clinical practices.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
- Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Förderung
- the National Natural Science Foundation of China
Zitieren
APA
Zhang, Q., Li, X., Wang, Y., Gao, N., Zhang, R., Wu, J., Wu, F., Song, P., Chen, M., Wang, G., & Gao, L. (2024). Dezocine as preemptive analgesia alleviates ultrapulse CO 2 fractional laser treatment induced pain in patients with acne scars. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.16410
Vancouver
Zhang Q, Li X, Wang Y, Gao N, Zhang R, Wu J, et al. Dezocine as preemptive analgesia alleviates ultrapulse CO 2 fractional laser treatment induced pain in patients with acne scars. Journal of Cosmetic Dermatology. 2024. doi:10.1111/jocd.16410
BibTeX
@article{Zhang2024,
author = {Zhang, Qian and Li, Xiaoqin and Wang, Yuanli and Gao, Ni and Zhang, Rongli and Wu, Jingjing and Wu, Fengqin and Song, Pu and Chen, Min and Wang, Gang and Gao, Lin},
title = {Dezocine as preemptive analgesia alleviates ultrapulse CO 2 fractional laser treatment induced pain in patients with acne scars},
journal = {Journal of Cosmetic Dermatology},
year = {2024},
doi = {10.1111/jocd.16410}
}
EUVIMED